CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Hbm Holdings Ltd is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Hbm Holdings Ltd
Level 54, Hopewell Centre, 183
Queen's Road East, Wan Chai
SUZHOU, JNG  China Ticker: 21422142
Business Summary
HBM Holdings Ltd is an investment holding company mainly engaged in the discovery and development of differentiated antibody therapeutics in immunology and oncology disease areas. The Company’s products include batoclimab, mainly used for immune thrombocytopenia (ITP), graves’ ophthalmopathy (GO), myasthenia gravis (MG), neuromyelitis optica spectrum disorder (NMOSD); and tanfanercept, mainly used for dry eye disease (DED). In addition, the Company researches and develops immuno-oncology portfolio, including internally developed next-generation immune-oncology assets targeting immune-desert, immune-excluded and inflamed tumors.
(Source: N-30D)

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
6/30/202412/31/2023Yes----

Industries
SIC Code Description
2834 Pharmaceutical preparations
8731 Commercial physical and biological research
6719 Offices of holding companies, not elsewhere classified

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Executive Chairman, Chief Executive Officer WangJingsong 57 7/1/2016 7/1/2016
Chief Financial Officer YingyingChen 47 7/1/2021 7/1/2021
Senior Vice President, Head of Technology Platform LileLiu 59 10/1/2018 10/1/2018
10 additional Officers and Directors records available in full report.

Subsidiaries
Business Name Address City State/Province Country
Harbour BioMed Netherlands B.V. Stationsplein 45, Unit A4.004 Rotterdam Netherlands

Business Names
Business Name
2142
6XY
Harbour BioMed
Harbour BioMed Netherlands B.V.

General Information
Number of Employees: 158 (As of 6/30/2024)
Outstanding Shares: 765,216,410 (As of 11/18/2024)
Stock Exchange: HKG


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Wednesday, November 20, 2024